Resolution of Orbitocerebral Aspergillosis during Combination Treatment with Voriconazole and Amphotericin Plus Adjunctive Cytokine Therapy

Journal of Pediatric Hematology/Oncology

Volumn 26, Issue 5, 2004, Pages 304-307

  Bethell, Delia ^a   Hall, Georgina ^a   Goodman, T Robin ^a   Klein, Nigel ^b   Pollard, Andrew J ^a,c  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Antifungal therapy; Aspergillosis; Cytokine therapy; Voriconazole

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ASPARAGINASE; CASPOFUNGIN; COTRIMOXAZOLE; CYTOKINE; DAUNORUBICIN; DEXAMETHASONE; FLUCONAZOLE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; KETOCONAZOLE; MERCAPTOPURINE; MICAFUNGIN; PREDNISOLONE; VINCRISTINE; VORICONAZOLE;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADJUVANT THERAPY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CANCER COMBINATION CHEMOTHERAPY; CANDIDIASIS; CASE REPORT; CENTRAL NERVOUS SYSTEM INFECTION; CHILDHOOD LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; ERYTHEMA; FACE; FEMALE; FEVER; FOOT MALFORMATION; HUMAN; IMMUNOMODULATION; INFECTIOUS COMPLICATION; MORBIDITY; MUCOSA INFLAMMATION; MYCOSIS; NEUTROPENIA; ORBIT INFECTION; PERIPHERAL NEUROPATHY; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; RETINA DETACHMENT; RIGOR; SCLERITIS; SIDE EFFECT; TREATMENT OUTCOME; ULTRASOUND; VISUAL DISORDER;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; BLINDNESS; BRAIN DISEASES; CHILD, PRESCHOOL; CYTOKINES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; NEUROASPERGILLOSIS; PYRIMIDINES; REMISSION INDUCTION; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TRIAZOLES;

EID: 2442599094     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200405000-00009     Document Type: Article

References (23)

1. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis. 1990;12:1147-1201.
2. Robinson MR, Fine HF, Ross ML, et al. Sino-orbital-cerebral aspergillosis in immunocompromised pediatric patients. Pediatr Infect Dis J. 2000;19:1197-1203.
3. Abbasi S, Shenep JL, Hughes WT, et al. Aspergillosis in children with cancer: a 34-year experience. Clin Infect Dis. 1999;29:1210-1219.
4. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34:563-571.
5. Coleman JM, Hogg GG, Rosenfeld JV, et al. Invasive central nervous system aspergillosis: cure with liposomal amphotericin B, itraconazole, and radical surgery-case report and review of the literature. Neurosurgery. 1995;36:858-863.
6. Ghannoum MA, Kuhn DM. Voriconazole-better chances for patients with invasive mycoses. Eur J Med Res. 2002;7:242-256.
7. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-415.
8. Ng A, Gadong N, Kelsey A, et al. Successful treatment of aspergillus brain abscess in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2000;17:497-504.
9. Cuccia V, Galarza M, Monges J. Cerebral aspergillosis in children. Report of three cases. Pediatr Neurosurg. 2000;33:43-48.
10. Schaffner A, Frick PG. The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. J Infect Dis. 1985;151:902-910.
11. George D, Kordick D, Miniter P, et al. Combination therapy in experimental invasive aspergillosis. J Infect Dis. 1993;168:692-698.
12. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis. 2003;36:1221-1228.
13. Keating GM, Jarvis B. Caspofungin. Drugs. 2001;61:1121-1129.
14. Kirkpatrick WR, Perea S, Coco BJ, et al. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother. 2002;46:2564-2568.
15. Serrano Mdel C, Valverde-Conde A, Chavez MM, et al. et al. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against Aspergillus spp. Diagn Microbiol Infect Dis. 2003;45:131-135.
16. Ellis M, Watson R, McNabb A, et al. Massive intracerebral aspergillosis responding to combination high-dose liposomal amphotericin B and cytokine therapy without surgery. J Med Microbiol. 2002;51:70-75.
17. Saulsbury FT. Successful treatment of aspergillus brain abscess with itraconazole and interferon-gamma in a patient with chronic granulomatous disease. Clin Infect Dis. 2001;32:E137-E139.
18. Bernhisel-Broadbent J, Camargo EE, Jaffe HS, et al. Recombinant human interferon-gamma as adjunct therapy forAspergillus infection in a patient with chronic granulomatous disease. J Infect Dis. 1991;163:908-911.
19. Rex JH, Bennett JE, Gallin JI, et al. In vivo interferon-gamma therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae. J Infect Dis. 1991;163:849-852.
20. Stevens DA. Combination immunotherapy and antifungal chemotherapy. Clin Infect Dis. 1998;26:1266-1269.
21. Gaviria JM, van Burik JA, Dale DC, et al. Comparison of interferon-gamma, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor for priming leukocyte-mediated hyphal damage of opportunistic fungal pathogens. J Infect Dis. 1999;179:1038-1041.
22. Mehrad B, Moore TA, Standiford TJ. Macrophage inflammatory protein-1 alpha is a critical mediator of host defense against invasive pulmonary aspergillosis in neutropenic hosts. J Immunol. 2000;165:962-968.
23. Denning DW, Griffiths CE. Mucocutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin Exp Dermatol. 2001;26:648-653.